广生堂(300436) - 2023 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2023 was ¥102,203,145.20, a decrease of 2.63% compared to the same period last year[4]. - Total operating revenue for Q3 2023 was ¥279,691,831.64, a decrease of 5.3% compared to ¥297,466,452.67 in the same period last year[23]. - Net profit for Q3 2023 was a loss of ¥211,862,700.38, compared to a loss of ¥81,637,182.37 in Q3 2022, indicating a significant decline in profitability[24]. - The net profit attributable to shareholders was -¥38,610,195.42, representing a 14.71% improvement year-on-year[4]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥35,034,707.93, showing a 24.13% reduction in losses compared to the previous year[4]. - The company reported a basic and diluted earnings per share of -¥1.2295, worsening from -¥0.4495 in the previous year[25]. - The company experienced an investment loss of ¥16,765,505.15, contrasting with a gain of ¥56,028,260.13 in the previous year, highlighting challenges in investment performance[24]. Assets and Liabilities - Total assets increased by 13.51% to ¥1,696,865,827.11 compared to the end of the previous year[4]. - As of September 30, 2023, total assets amount to RMB 1,696,865,827.11, an increase from RMB 1,494,844,681.01 at the beginning of the year[19]. - The total liabilities increased to ¥964,580,103.11 from ¥539,221,756.63, reflecting a significant rise in financial obligations[24]. - The company's total equity decreased to ¥732,285,724.00 from ¥955,622,924.38, indicating a decline in shareholder value[24]. Cash Flow - Cash flow from operating activities for the first nine months was -¥163,008,732.85, a decline of 109.72% compared to the same period last year[11]. - The net cash outflow from operating activities was -163,008,732.85 CNY, compared to -77,728,318.34 CNY in the previous year, indicating a significant increase in cash outflow[27]. - The total cash outflow from operating activities amounted to 497,773,538.50 CNY, an increase from 424,089,560.37 CNY year-over-year[27]. - The cash and cash equivalents at the end of the period decreased to 208,326,095.89 CNY from 297,962,664.65 CNY, showing a decline of approximately 30%[27]. - Total cash inflow from financing activities was 558,158,269.57 CNY, up from 270,302,895.14 CNY year-over-year, reflecting a strong financing position[27]. - The company reported a net cash flow from financing activities of 351,524,153.04 CNY, significantly higher than 143,542,359.96 CNY from the same period last year[27]. Research and Development - The company's R&D expenses for the first nine months of 2023 were ¥236,068,398.60, a 94.69% increase year-on-year, reflecting a focus on innovative drug development[10]. - Research and development expenses were reported at ¥92,260,063.89, down from ¥120,149,542.08, suggesting a reduction in investment in innovation[24]. - The company is advancing its clinical research for the innovative drug series under the "Dengfeng Plan" for hepatitis B treatment[9]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 20,128[13]. - Fujian Aohua Group Co., Ltd. holds 22.02% of shares, amounting to 35,068,651 shares, with 22,610,000 shares pledged[13]. Financing and Investments - The company’s long-term borrowings increased by 163.94% to ¥221,811,600.00, indicating a need for additional financing for operations[10]. - The company approved the acquisition of 5.8333% equity in Jiangsu Zhongxing Pharmaceutical Co., Ltd. for RMB 10.6 million, making it a wholly-owned subsidiary[17]. - The company used RMB 25 million of idle raised funds to temporarily supplement working capital[16]. Operational Costs - Total operating costs increased slightly to ¥449,856,289.57 from ¥446,059,633.58, with operating costs specifically at ¥116,218,252.14, down from ¥124,823,574.26[23]. - The company reported a significant increase in inventory, which rose by 87.09% to ¥128,458,132.32, primarily due to increased preparations for the GST-HG171 project[10]. - Inventory increased significantly to RMB 128,458,132.32 from RMB 68,661,452.52[20]. - The cash paid to employees increased to 114,871,432.51 CNY from 94,840,103.21 CNY, reflecting a rise of approximately 21%[27]. - The cash paid for taxes was 45,972,440.23 CNY, up from 27,706,490.98 CNY, indicating a significant increase in tax obligations[27].